Pharmaceuticals
Foxx Life Sciences Announces Opening of New Asia Headquarters in India
SALEM, New Hampshire, Nov. 17, 2020 /PRNewswire/ -- Foxx Life Sciences announced on Tuesday that it will open the new internationalAsia headquarters in Medchal,Hyderabad, India. The latest expansion comes with strong growth and performance inAsia and the continued expansion of Biopharmaceutical ...
2020-11-17 21:00
1177
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
INDIANAPOLIS and INCHEON, South Korea, Nov. 17, 2020 /PRNewswire/ -- Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making ...
2020-11-17 20:00
1573
Late-Breaking Study Results of the Supreme HT™ Healing-Targeted DES Demonstrated Equivalent Outcomes with Exceptional Safety
TIANJIN, China, Nov. 17, 2020 /PRNewswire/ -- SINOMED® today announced that Prof.Alexandra Lansky from the Yale School of Medicine, USA, presented data from its first inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) Drug-Eluting Stent, t...
2020-11-17 18:49
2077
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China
TAIPEI, Nov. 17, 2020 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced today that it has entered into an exclusive license agreement with GenScience Pharmaceuticals ("GenSci") - a wholly-owned subsidiary of Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) - for ...
2020-11-17 17:51
1978
CPhI & P-MEC China 2020 adapts to customer needs with hybrid pharma event
SHANGHAI, Nov. 17, 2020 /PRNewswire/ -- CPhI & P-MEC China
2020-11-17 16:29
1593
CPhI & P-MEC China 2020 adapts to customer needs with hybrid pharma event
SHANGHAI, Nov. 17, 2020 /PRNewswire/ -- CPhI & P-MEC China
2020-11-17 15:00
1599
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
* STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary Medicine for the treatment of non-metastatic mast cell tumours (MCT) in dogs, making it the first pharmaceutical treatment available for all grades of canine non-metastati...
2020-11-17 11:51
3086
Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus
SHANGHAI, Nov. 17, 2020 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inShanghai, China, announced that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase Ib/IIa clinical study of KPG-818 in patients with Systemic Lup...
2020-11-17 09:00
2670
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...
2020-11-17 01:09
1394
Covis Group Completes Acquisition of AMAG Pharmaceuticals
LUXEMBOURG and ZUG, Switzerland, Nov. 16, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") today announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) through the successful tender offer for all of the outstanding shares of common stock of AMAG at$13.75 per s...
2020-11-16 22:43
3973
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases
MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...
2020-11-16 21:42
2798
Happiness Biotech Starts Offering Kingdomway Coenzyme Q10 in Its Experience Stores
NANPING, China, Nov. 16, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company's experience stores started offering Coenzyme Q10 - a best-selling product from ...
2020-11-16 21:00
3104
PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020. ...
2020-11-16 21:00
1408
Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society
SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company today announced that the company will present the phase II clinical trial results of Tanfanercept (HBM9036) at the 25th Congress of Chinese Ophthalmological Society (CCOS) held ...
2020-11-16 20:17
3188
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
PLYMOUTH MEETING, Pa., Nov. 16, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Dru...
2020-11-16 20:00
3805
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology
SAN FRANCISCO and SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2020-11-16 08:00
5633
PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19
– Oral treatment with novel dual-mechanism of action has the potential to address the two critical elements of COVID-19: viral replication and uncontrolled inflammatory response – – Randomized, double-blind, placebo-controlled, Phase 2/3 clinical study with two stages initiated at several sites ...
2020-11-16 05:00
1570
Biortus Announces Round A Financing and Launches Global Cryo-EM Innovation Center
WUXI, China, Nov. 13, 2020 /PRNewswire/ -- Wuxi Biortus Biosciences Co. Ltd. ("Biortus"), a global leader in structural biology service for drug discovery, recently closed round A financing withUS$15 million investment led by Bayland Capital, and the fund will be used to establish a global cryo-E...
2020-11-14 12:40
8760
China Pharma Holdings, Inc. Reports Third Quarter 2020 Financial Results
HAIKOU, China, Nov. 13, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the quarter...
2020-11-14 05:10
8415
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, inEurope FLORENCE, Italy, Nov. 14...
2020-11-14 01:03
4318
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
